• Earlier in May 2026, Nanjing Leads Biolabs announced that partner Dianthus Therapeutics selected Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as the first priority indications for clinical development of LBL-047 (DNTH212), supported by an upsized underwritten public offering that raised about US$719,000,000 in March 2026.
• This bifunctional fusion protein, designed to simultaneously target plasmacytoid dendritic cells and BAFF/APRIL pathways, positions Dianthus to pursue multiple high unmet-need autoimmune conditions under its exclusive global rights outside Greater China.
• We’ll now examine how Dianthus’ focus on LBL-047 as a core autoimmune asset shapes the company’s broader investment narrative.

Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

What Is Dianthus Therapeutics' Investment Narrative?

To own Dianthus today, you have to believe in a concentrated, binary story around complement inhibition (claseprubart) and now a broadened autoimmune platform with LBL-047 at its center. The May 2026 update from Nanjing Leads Biolabs formally elevates LBL-047 into that core narrative, clarifying that Sjögren’s, SLE and dermatomyositis will sit alongside CIDP and other neuromuscular indications as the key clinical value drivers. Backed by roughly US$719,000,000 raised in March, the company looks better funded for an aggressive, multi-indication plan, which could make upcoming readouts in CAPTIVATE and early LBL-047 data the main near term catalysts. At the same time, a widening net loss, heavy recent dilution and dependence on unproven late stage assets remain central risks that this latest announcement does not remove.

However, investors should be aware of how recent dilution and rising losses affect the risk profile. Our expertly prepared valuation report on Dianthus Therapeutics implies its share price may be too high.

Exploring Other Perspectives

The Simply Wall St Community’s single fair value estimate of US$125.83 per share reflects one detailed but narrow view, while the recent focus on LBL-047 and continued losses underline why many market participants may reach very different conclusions and why it can be useful to compare multiple viewpoints before forming a view on Dianthus.

Explore another fair value estimate on Dianthus Therapeutics - why the stock might be worth just $125.83!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Dianthus Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Dianthus Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Dianthus Therapeutics' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.